PMID- 33521054
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210202
IS  - 2296-889X (Print)
IS  - 2296-889X (Electronic)
IS  - 2296-889X (Linking)
VI  - 7
DP  - 2020
TI  - Efficacy and Safety of TACE Combined With Sorafenib Plus Immune Checkpoint 
      Inhibitors for the Treatment of Intermediate and Advanced TACE-Refractory 
      Hepatocellular Carcinoma: A Retrospective Study.
PG  - 609322
LID - 10.3389/fmolb.2020.609322 [doi]
LID - 609322
AB  - Purpose: The study aims to retrospectively investigate the efficacy and safety of 
      sorafenib combined with transarterial chemoembolization (TACE) (TACE+Sor) vs. 
      TACE combined with sorafenib plus immune checkpoint inhibitors (TACE+Sor+ICIs) in 
      treating intermediate and advanced TACE-refractory hepatocellular carcinoma 
      (HCC). Materials and Methods: This study was approved by the ethics committee of 
      Lisui Hospital, Zhejiang University, China. From January 2016 to June 2020, 51 
      eligible patients with intermediate or advanced TACE-refractory HCC received 
      TACE+Sor (n = 29) or TACE+Sor+ICIs (n = 22). The differences in tumor response, 
      adverse events (AEs), progression-free survival (PFS), and overall survival (OS) 
      were compared between the two groups. Factors affecting PFS and OS were 
      determined by Cox regression. Results: The disease control rate was higher in the 
      TACE+Sor+ICIs group than in the TACE+Sor group (81.82 vs. 55.17%, P = 0.046). 
      Compared with the TACE+Sor group, PFS and OS were prolonged in the TACE+Sor+ICIs 
      group (median PFS: 16.26 vs. 7.30 months, P < 0.001; median OS: 23.3 vs. 13.8 
      months, P = 0.012). Multivariate analysis showed that BCLC stage, 
      alpha-fetoprotein and treatment were independent factors of PFS; BCLC, Child-Pugh 
      class, ablation after disease progression and treatment were independent 
      predictive factors of OS. Four patients in the TACE+Sor+ICIs group and three 
      patients in the TACE+Sor group suffered from dose reduction or interruption 
      (18.18 vs. 10.34%, P = 0.421). The incidence of ICI-related AEs in the 
      TACE+Sor+ICIs group was well-controlled. Conclusion: The therapeutic schedule of 
      TACE+Sor+ICIs demonstrated efficacy and safety in intermediate and advanced 
      TACE-refractory HCC.
CI  - Copyright (c) 2021 Zheng, Fang, Wu, Chen, Chen, Weng, Wu, Song, Zhao and Ji.
FAU - Zheng, Liyun
AU  - Zheng L
AD  - Zhejiang Provincial Key Laboratory of Imaging Diagnosis and Minimally Invasive 
      Intervention Research, Lishui Hospital of Zhejiang University, Lishui, China.
FAU - Fang, Shiji
AU  - Fang S
AD  - Zhejiang Provincial Key Laboratory of Imaging Diagnosis and Minimally Invasive 
      Intervention Research, Lishui Hospital of Zhejiang University, Lishui, China.
FAU - Wu, Fazong
AU  - Wu F
AD  - Zhejiang Provincial Key Laboratory of Imaging Diagnosis and Minimally Invasive 
      Intervention Research, Lishui Hospital of Zhejiang University, Lishui, China.
FAU - Chen, Weiqian
AU  - Chen W
AD  - Zhejiang Provincial Key Laboratory of Imaging Diagnosis and Minimally Invasive 
      Intervention Research, Lishui Hospital of Zhejiang University, Lishui, China.
FAU - Chen, Minjiang
AU  - Chen M
AD  - Zhejiang Provincial Key Laboratory of Imaging Diagnosis and Minimally Invasive 
      Intervention Research, Lishui Hospital of Zhejiang University, Lishui, China.
FAU - Weng, Qiaoyou
AU  - Weng Q
AD  - Zhejiang Provincial Key Laboratory of Imaging Diagnosis and Minimally Invasive 
      Intervention Research, Lishui Hospital of Zhejiang University, Lishui, China.
FAU - Wu, Xulu
AU  - Wu X
AD  - Zhejiang Provincial Key Laboratory of Imaging Diagnosis and Minimally Invasive 
      Intervention Research, Lishui Hospital of Zhejiang University, Lishui, China.
FAU - Song, Jingjing
AU  - Song J
AD  - Zhejiang Provincial Key Laboratory of Imaging Diagnosis and Minimally Invasive 
      Intervention Research, Lishui Hospital of Zhejiang University, Lishui, China.
FAU - Zhao, Zhongwei
AU  - Zhao Z
AD  - Zhejiang Provincial Key Laboratory of Imaging Diagnosis and Minimally Invasive 
      Intervention Research, Lishui Hospital of Zhejiang University, Lishui, China.
FAU - Ji, Jiansong
AU  - Ji J
AD  - Zhejiang Provincial Key Laboratory of Imaging Diagnosis and Minimally Invasive 
      Intervention Research, Lishui Hospital of Zhejiang University, Lishui, China.
LA  - eng
PT  - Journal Article
DEP - 20210115
PL  - Switzerland
TA  - Front Mol Biosci
JT  - Frontiers in molecular biosciences
JID - 101653173
PMC - PMC7843459
OTO - NOTNLM
OT  - TACE-refractory
OT  - adverse events
OT  - hepatocellular carcinoma
OT  - immune checkpoint inhibitors
OT  - overall survival
OT  - progression-free survival
OT  - sorafenib
OT  - transarterial chemoembolization
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/02/02 06:00
MHDA- 2021/02/02 06:01
PMCR- 2020/01/01
CRDT- 2021/02/01 06:00
PHST- 2020/09/23 00:00 [received]
PHST- 2020/12/10 00:00 [accepted]
PHST- 2021/02/01 06:00 [entrez]
PHST- 2021/02/02 06:00 [pubmed]
PHST- 2021/02/02 06:01 [medline]
PHST- 2020/01/01 00:00 [pmc-release]
AID - 10.3389/fmolb.2020.609322 [doi]
PST - epublish
SO  - Front Mol Biosci. 2021 Jan 15;7:609322. doi: 10.3389/fmolb.2020.609322. 
      eCollection 2020.